



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/227,881	01/11/1999	THAI D. NGUYEN	07425.0057	7578
28381	7590	09/15/2004	EXAMINER	
ARNOLD & PORTER LLP ATTN: IP DOCKETING DEPT. 555 TWELFTH STREET, N.W. WASHINGTON, DC 20004-1206				SCHULTZ, JAMES
ART UNIT		PAPER NUMBER		
		1635		

DATE MAILED: 09/15/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	09/227,881	NGUYEN ET AL.	
	Examiner	Art Unit	
	J. D. Schultz, Ph.D.	1635	

All Participants:

Status of Application: _____

(1) J. D. Schultz, Ph.D. (3) _____.

(2) Joseph Ricigliano. (4) _____.

Date of Interview: 14 September 2004

Time: 10:35 AM

Type of Interview:

- Telephonic
 Video Conference
 Personal (Copy given to: Applicant Applicant's representative)

Exhibit Shown or Demonstrated: Yes No

If Yes, provide a brief description: .

Part I.

Rejection(s) discussed:

N/A

Claims discussed:

N/A

Prior art documents discussed:

N/A

Part II.


SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

See Continuation Sheet

Part III.

- It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
 It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

(Examiner/SPE Signature)

 Sept. 14, 2004
 (Applicant/Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: In a previous interview, applicants had requested the rejoinder of claims drawn to SEQ ID NO: 34 with the claim set under examination, drawn to SEQ ID NO: 3. It was agreed that such rejoinder would be considered if it could be shown that the two sequences were related. During the instant interview, Joseph Ricigliano indicated that, on evidence of a BLASTn search, that SEQ ID NO: 34 consists of nucleotides 1-5271 of SEQ ID NO: 3. Accordingly, since SEQ ID NO: 34 is considered to be a fragment of SEQ ID NO: 3, claims drawn to both SEQ ID NOS: 3 and 34 will be examined in the next Official action... .